Similar articles

• Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.

  Lewis RL, Canafax DM, Pettit KG, DiCesare J, Kaniecki DJ, Arnold RJ, Roberts MS. Lewis RL, et al. Transplant Proc. 1996 Aug;28(4):2214-7. Transplant Proc. 1996. PMID: 8769203 Clinical Trial. No abstract available.
• Economic analysis of Neoral in de novo renal transplant patients in Canada.

  Kingma I, Ludwin D, Dandavino R, Wolff JL, Loertscher R, Beauregard-Zollinger L, Bacquet P, Boucher S, Rivière M. Kingma I, et al. Clin Transplant. 1997 Feb;11(1):42-8. Clin Transplant. 1997. PMID: 9067694 Clinical Trial.
• Economic analysis of Sandimmune Neoral in Canada in stable renal transplant patients.

  Keown P, Lawen JG, Landsberg D, Beauregard-Zollinger L, Rivière M, Leclerc C, Hardens M. Keown P, et al. Transplant Proc. 1995 Apr;27(2):1845-8. Transplant Proc. 1995. PMID: 7725530 No abstract available.
• Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation.

  Kahan BD. Kahan BD. Transplant Proc. 1996 Aug;28(4):2143-6. Transplant Proc. 1996. PMID: 8769182 Review. No abstract available.
• Composite outcomes in renal transplantation using cyclosporine.

  Keown PA. Keown PA. Transplant Proc. 2004 Mar;36(2 Suppl):35S-39S. doi: 10.1016/j.transproceed.2004.01.060. Transplant Proc. 2004. PMID: 15041304 Review. No abstract available.